


# Annual Results 2022

Swiss Re media conference presentation  
Zurich, 17 February 2023



## Focus areas of Annual Results 2022



FY 2022  
results



Capital  
actions



P&C Re  
renewals




2023 financial  
targets

## 2022 result impacted by significant headwinds



- <sup>1</sup> Pre-tax impact of economic inflation on underwriting results across P&C Reinsurance (USD 1.0bn) and Corporate Solutions (USD 0.1 bn) based on prior-year and current-year inflation reserves established in the financial year 2022. Does not include implicit impacts of economic inflation on actual reported claims
- <sup>2</sup> Pre-tax mark-to-market impact as part of net realised investment losses, across equity securities (net of hedges), private equity, and Principal Investments
- <sup>3</sup> Pre-tax COVID-19 losses in L&H Reinsurance, predominantly in Q1 2022
- <sup>4</sup> Pre-tax higher-than-expected large nat cat losses in P&C Reinsurance, net of favourable prior-year development

## Solid Q4 performance across the Group





		<b>FY 2022 key figures</b>	<b>Q4 2022 key figures</b>
<b>P&amp;C Reinsurance</b>	Combined ratio	102.4%	91.0%
	Normalised <sup>3</sup> combined ratio	96.9%	98.9%
<b>L&amp;H Reinsurance</b>	Net income (USD)	416m	195m
<b>Corporate Solutions</b>	Combined ratio	93.1%	93.1%
<b>Swiss Re Group</b>	Return on equity	2.6%	24.6%

<sup>1</sup> Net premiums earned and fee income

<sup>2</sup> At constant fx rates

<sup>3</sup> Assuming an average large nat cat loss burden and excluding prior-year reserve development. FY and Q4 2022 include current-year inflation reserves of 1.0%pts and 1.8%pts, respectively, as well as impact from the Ukraine war of 0.8%pts and 0.6%pts, respectively

# 2022 P&C Reinsurance underwriting result impacted by economic inflation and elevated nat cat losses



## Underwriting performance in 2022

- Reported combined ratio impacted by higher-than-expected economic inflation (USD 1.0bn<sup>3</sup>, 4.5%pts), elevated large nat cat losses (USD 0.5bn, 2.4%pts<sup>4</sup>) and reserves related to the Ukraine war (USD 0.2bn, 0.8%pts)
- Normalised combined ratio in 2022 above target of <94%, mostly due to the impact of economic inflation

<sup>1</sup> Assuming an average large nat cat loss burden and excluding (i) prior-year reserve development and (ii) COVID-19 impact in 2020 and 2021; FY 2022 includes impact from the Ukraine war of 0.8%pts


<sup>2</sup> Including prior-year development US GAAP nat cat combined ratio is 78%

<sup>3</sup> Includes prior-year inflation reserves (USD 0.8bn) and current-year inflation reserves (USD 0.2bn) established in the financial year 2022, in the form of incurred but not reported (IBNR) reserves. Does not include implicit impacts of economic inflation on actual reported claims

<sup>4</sup> Higher-than-expected large nat cat losses, net of favourable prior-year development



## Corporate Solutions delivered a resilient result




### Underwriting performance in 2022

- Reported combined ratio of 93.1%<sup>1</sup> outperformed target of <95%
- Combined ratio impacted by reserves related to the Ukraine war (USD 0.1 bn, 2.7%pts) and higher-than-expected economic inflation (USD 0.1 bn<sup>2</sup>, 2.0%pts), partially offset by favourable prior-year development (USD 0.2bn, 3.1 %pts)
- Risk-adjusted price quality improved by ~3% in 2022

<sup>1</sup> FY 2022 pro forma combined ratio of 91.9%, including medical business of Elips Versicherungen AG in Ireland and excluding parts of elipsLife sold to Swiss Life International (effective 1 July 2022)

<sup>2</sup> Includes prior-year inflation reserves (USD ~60m) and current-year inflation reserves (USD ~50m) established in the financial year 2022, in the form of incurred but not reported (IBNR) reserves. Does not include implicit impacts of economic inflation on actual reported claims

 Reserving actions taken on economic inflation throughout the year, largely offset by positive reserve development of the broader P&C portfolio



Prior-year development in 2022


- Cumulative inflation IBNR<sup>2</sup> reserves of USD 1.0bn established since Q4 2021 (USD 0.8bn<sup>3</sup> in 2022), addressing potential adverse impacts from elevated economic inflation in 2022 and higher expected economic inflation in 2023
- Strengthening of US liability reserves, but of lower magnitude compared to previous years
- Continued favourable reserve development of non-liability book
- Overall positive net prior-year development of USD 0.1bn in Q4 2022, with further inflation IBNR reserves of USD 0.3bn addressing inflationary pressure on wage and medical costs in long-tail lines, fully offset by releases in the rest of the book

<sup>1</sup> Includes P&C Reinsurance and Corporate Solutions; positive figures represent reserve releases, negative figures reserve strengthening

<sup>2</sup> IBNR = Incurred but not reported

<sup>3</sup> Additional current-year inflation reserves of USD 0.3bn established in the financial year 2022 across P&C Reinsurance and Corporate Solutions

 Third consecutive quarter of strong L&H Reinsurance profitability, supported by waning COVID-19 impacts



Performance in 2022


- Reported net income of USD 416m for FY 2022 exceeded target of USD ~300m, supported by positive contributions of Americas, partially offset by adverse experience in Asia
- FY 2022 result includes COVID-19 losses of USD 588m, predominantly in Q1 2022 (USD 501 m)

 While the reinvestment yield is expected to have come down from Q4 2022 peak, current interest rate levels continue to provide uplift to recurring income

5.1%


fixed income reinvestment  
yield in Q4 2022

Quarterly recurring income  
increased by USD ~170m  
in Q4 2022 vs. Q4 2021




 Dividend of USD 6.40 proposed based on very strong capital position and positive outlook

Swiss Re’s capital management priorities remain unchanged



Group SST ratio<sup>1</sup> development



Proposed regular dividend per share<sup>3</sup>

**USD 6.40**  
to be paid in 2023

<sup>1</sup> Group SST ratio calculation: SST available capital / SST economic target capital = (SST risk-bearing capital – MVM) / (SST target capital – MVM)  
<sup>2</sup> Group SST target range was introduced in 2021  
<sup>3</sup> Subject to AGM 2023 approval

# January renewals outcome reflects elevated risk environment

## Pricing

+18%

nominal price increase  
more than offset higher loss  
assumptions of 13%

## Volume

+13%

premium volume growth of  
P&C Reinsurance treaty book<sup>1</sup>

## Economic profitability

USD  
+0.8<sub>bn</sub>

higher expected economic pre-tax  
earnings<sup>2</sup> from improved nominal  
technical result and discounting<sup>3</sup>

## Structure & terms



Increased  
**attachment points**



Tightened  
**terms & conditions**


Note: figures are gross of external retro

<sup>1</sup> Excluding business reported on a deposit accounted basis and facultative business

<sup>2</sup> January 2023 renewals outcome vs. up for renewal

<sup>3</sup> Discounting at risk-free interest rates

# P&C Reinsurance achieved strong price increases in the January renewals



- 48% of Swiss Re’s reinsurance treaty business renewed in January
- +18% price increase, with rate increases most pronounced in nat cat
- +13% higher loss assumptions reflect prudent view on inflation and loss model updates
- +5% net price increase (undiscounted) translates into ~3 percentage points benefit to the combined ratio (underwriting year)
- +13% premium volume growth
- Cancelled and not placed business reflects targeted reductions in property (including nat cat) and casualty
- Expected economic pre-tax earnings increased by USD 0.8bn in January 2023 vs. up for renewal portfolio

Note: figures are gross of external retro

<sup>1</sup> Price change defined as change in premiums net of commissions/ claims; price change assumes constant portfolio mix and excludes discounting

<sup>2</sup> Delta to January 2022 outcome (as in FY 2021 results presentation) reflects fx movements and multi-year deals that expired in 2023

<sup>3</sup> Treaty business only; excluding business reported on a deposit accounted basis (USD 2.7bn) and facultative business (USD 0.7bn)

 January renewals book features improved pricing and benefit of higher interest rates, while focus on portfolio quality was maintained

Gross premium volume by line of business<sup>1</sup> (USD bn)

	Up for renewal in January	Premium volume change	Outcome January renewals	Economic combined ratio improvement <sup>3</sup>
Nat cat	1.8	+21%	2.2	+++
Property <sup>2</sup>	2.0	+12%	2.2	+
Specialty	1.8	+10%	2.0	+
Casualty	3.3	+11%	3.7	++
<b>Total</b>	<b>9.0</b>	<b>+13%</b>	<b>10.2</b>	<b>++</b>

Gross premium volume by region<sup>1</sup> (USD bn)

	Up for renewal in January	Premium volume change	Outcome January renewals
Americas	4.1	+0%	4.1
EMEA	3.8	+21%	4.6
Asia	1.1	+35%	1.4
<b>Total</b>	<b>9.0</b>	<b>+13%</b>	<b>10.2</b>

- **Nat cat:** increase in premium driven by rate improvements; reduced exposure to low-attaching nat cat and aggregate covers; budget for expected large nat cat losses<sup>4</sup> of USD 1.9bn for P&C Reinsurance in 2023
- **Property<sup>2</sup>:** premium growth in EMEA and Asia, partially offset by cautious approach to proportional business given inflationary environment
- **Specialty:** growth supported by rate increases, particularly in cyber, aviation and marine; more cautious approach to credit & surety and cyber
- **Casualty:** higher volume due to rate improvements and increase in Asia motor; remained cautious on US Large Corporate Risks (LCR)

<sup>1</sup> Treaty business only

<sup>2</sup> Excluding nat cat

<sup>3</sup> Economic combined ratio improvement reflects price change (undiscounted), increased loss assumptions and impact of discounting (at risk-free interest rates)

<sup>4</sup> Large nat cat losses are defined as losses USD >20m in P&C Reinsurance



# Financial targets reflect positive outlook across our three business segments

## New 2023 financial targets

**P&C  
Reinsurance**

Reported combined ratio

**<95%**

**L&H  
Reinsurance**

Net income

**USD ~900m**

**Corporate  
Solutions**

Reported combined ratio

**<94%**

**Swiss Re  
Group**

Net income<sup>1</sup>

**USD >3bn**

## Unchanged multi-year Group targets

**14%**

Return on equity<sup>2</sup>  
in 2024

**10%**

ENW per share  
growth<sup>3</sup> per year


<sup>1</sup> Swiss Re will maintain a ROE target. Given current impact of interest rates on US GAAP shareholders' equity, a corresponding net income target for 2023 is provided

<sup>2</sup> US GAAP ROE target announced in February 2022, which was based on an expected shareholders' equity higher than the year-end 2021 amount of USD 23.6bn


<sup>3</sup> Calculated as: (current-year closing ENW per share + current-year dividends per share) / (prior-year closing ENW per share + current-year opening balance sheet adj. per share)



# The Group targets a US GAAP net income of USD >3bn in 2023



 P&C Reinsurance targets a reported US GAAP combined ratio of <95% in 2023



# L&H Reinsurance targets a US GAAP net income of USD ~900m in 2023




# New organisational set-up mirrors our Group strategy – putting clients first, and expanding our focus to risk insights and partnerships

## Rationale

- **Increased proximity to clients and partners** by shifting decision-making authority closer to them
- **Simpler, more nimble set-up** empowering employees, speeding up decision-making and improving accountability
- **Sharpened focus** on delivering on business priorities and performance
- **Cost savings** are expected as a result of these changes, supporting the ambition to keep costs flat while growing our businesses

## Streamlined set-up of Business Units<sup>1</sup>



- Significant streamlining of senior management structure
- 22 Market Units across P&C Reinsurance and L&H Reinsurance will be responsible for client management, underwriting and claims
- Global Clients and Solutions Unit will focus on major clients and strategic growth areas<sup>2</sup>
- No change to the set-up of Corporate Solutions
- No change to reporting of external financial results (including segment reporting)



# Financial highlights

# Key figures

USD m, unless otherwise stated

	<b>P&amp;C Re</b>	<b>L&amp;H Re</b>	<b>Corporate Solutions</b>	<b>Group items</b>	<b>Total FY 2022</b>	<b>Total FY 2021</b>
• Premiums earned and fee income	22 028	14 984	5 482	624	<b>43 118</b>	<b>42 726</b>
• Net income/loss	312	416	486	-742	<b>472</b>	<b>1 437</b>
• Return on investments	1.4%	3.2%	1.4%	0.9%	<b>2.0%</b>	<b>3.2%</b>
• Combined ratio	102.4%		93.1%			
• Return on equity					<b>2.6%</b>	<b>5.7%</b>
• Earnings per share	(USD)				<b>1.63</b>	<b>4.97</b>
	(CHF)				<b>1.63</b>	<b>4.52</b>
• Shareholders' equity					<b>12 699</b>	<b>23 568</b>
<i>of which unrealised gains/losses</i>					<b>-6 935</b>	<b>2 803</b>
• Book value per share	(USD)				<b>43.94</b>	<b>81.56</b>
	(CHF)				<b>40.65</b>	<b>74.30</b>


# P&C Reinsurance

# P&C Reinsurance result impacted by economic inflation and elevated nat cat losses


Net premiums earned

**USD 22.0bn**  
in 2022

USD 21.9bn  
in 2021




Combined ratio (%)



- FY 2022 large nat cat losses 3.7%pts<sup>4</sup> above expectation. Negative prior year development of 1.8%pts. Impact from the Ukraine war of 0.8%pts
- Normalised<sup>2</sup> combined ratio in 2022 well above target of <94%, primarily driven by higher-than-expected economic inflation

- Net premiums earned increased slightly, supported by volume growth and price increases while fx movements were unfavourable (+4.1% at constant fx rates)
- Underwriting result impacted by higher-than-expected economic inflation, elevated large nat cat losses and reserves related to the Ukraine war
- Investment result reflects negative mark-to-market impacts on listed equities as well as lower contribution from private equity investments

Net income (USD m)



<sup>1</sup> Net operating margin = EBIT / total revenues


<sup>2</sup> Assuming an average large nat cat loss burden and excluding (i) prior-year reserve development and (ii) COVID-19 impact in 2020 and 2021

<sup>3</sup> 2021 figures restated for Group items re-segmentation (figures before 2021 are not restated)

<sup>4</sup> Excluding favourable prior-year development


# P&C Reinsurance strategy in action

Portfolio split by region and line of business  
(% of net premiums earned)



## CORE


US GAAP cost ratio<sup>1</sup>(%)



- Efficiency gains across the value chain through services tailored towards client needs combined with smart and lean processes
- Continuous reallocation of resources to key growth opportunities and geographic markets

## SOLUTIONS


Economic earnings contribution (USD m)



- Expansion and growth of property and specialty solutions, including solutions such as US Flood, CatNet, and Digital Engineering
- Initial market success in application of fee-based remuneration model for various P&C solutions

## TRANSACTIONS

Economic earnings contribution (USD m)



- A strong year for production of P&C transactions with a well-diversified portfolio of ~160 clients in 2022
- Demand continues to be strong for capital management (prospective and retrospective) and nat cat transactions




# L&H Reinsurance

# L&H Reinsurance returned to profitability despite material COVID-19 losses


Net premiums earned and fee income

**USD 15.0bn**  
in 2022

USD 15.0bn  
in 2021




Recurring income yield<sup>2</sup> and ROI (%)



- 2022 ROI driven by recurring investment income
- Return to profitability despite material COVID-19-related claims

Net income (USD m)



- Net premiums earned and fee income remained flat due to unfavourable fx movements (+5.1% at constant fx rates)
- Underwriting performance reflects significantly lower impact from COVID-19 (USD 0.6bn in 2022 vs. USD 2.0bn in 2021)
- Lower investment result mainly due to negative mark-to-market impacts on listed equities, partially compensated by higher realised gains



<sup>1</sup> Net operating margin = EBIT / (total revenues – net investment result unit-linked)

<sup>2</sup> From 2021 recurring income yield replaced running yield, adding income from short-term investments, listed equity dividends and real estate investment income to fixed income and loans already included in running yield metric

<sup>3</sup> FY 2021 figures restated for Group items re-segmentation (figures before 2021 are not restated)


# L&H Reinsurance strategy in action

Portfolio split by region and line of business  
(% of net premiums earned and fee income)



## CORE


US GAAP cost ratio<sup>1</sup> (%)



- Active cost management, scalability and growth will further improve our cost ratios
- Continuous reallocation of resources to key growth opportunities and geographic markets

## SOLUTIONS


Economic earnings contribution (USD m)



- Economic contribution driven by Magnum, and diversification across regions
- Focus on product design and development of Data Driven Underwriting, Claims and Customer Engagement solutions

## TRANSACTIONS

Economic earnings contribution (USD m)



- Lower new business volume following two exceptional years, mainly driven by softening longevity market
- Dynamic macroeconomic environment increases clients' demand for capital management




# Corporate Solutions

# Corporate Solutions outperformed its combined ratio target


Net premiums earned

**USD 5.5bn**  
in FY 2022

USD 5.3bn  
in FY 2021




Combined ratio (%)



- FY 2022 combined ratio reflects large man-made losses of 4.4%pts, large nat cat losses of 4.2%pts, impact from the Ukraine war of 2.7%pts, and favourable prior-year development of 3.1%pts
- Combined ratio in 2022 outperformed its target of <95%

- Despite partial sale of elipsLife, net premiums earned increased by 2.6%, benefitting from new business growth in selected focus portfolios along with continuous earn-through of previously realised rate increases (+14.8% pro-forma<sup>2</sup> at constant fx rates)
- Continued solid underwriting result despite reserves related to Ukraine war and higher-than-expected economic inflation, confirming the improved resilience of the underlying business. Lower underwriting margin vs. 2021 driven by less favourable prior-year development
- Operating expense ratio improvement due to diligent cost management and fx rate developments

Net income (USD m)




<sup>1</sup> Net operating margin = EBIT / total revenues

<sup>2</sup> Including medical business of Elips Versicherungen AG in Ireland and excluding parts of elipsLife sold to Swiss Life International (effective 1 July 2022)

<sup>3</sup> FY 2020 figures restated to include elipsLife which as of 1 January 2021 is reported as part of Corporate Solutions (figures before 2020 are not restated)


# Corporate Solutions strategy in action

Portfolio split by region and line of business  
(% of net premiums earned and fee income)



## Reserving adequacy restored


Net prior-year reserve development (as % of premiums)



- Reinforced portfolio steering framework across costing, underwriting, reserving and claims

## Operational excellence with improved cost efficiency


Operating expense ratio (%)



- Expense ratio improved further as top line growth outpaced investments in strategic initiatives

## Capturing value from differentiating assets

Int. Programme Lead (# of programmes)




- Profitable growth in International Programme Lead business leveraging proprietary technology platform

iptiQ


# iptiQ continued its growth trajectory

Gross premiums written<sup>1</sup> (USD m)




- Gross premiums written increased 17.7% year-on-year (27.8% at constant fx rates), with policy count 33.0% higher vs. 2021
- All regions contributed to 2022 growth

In-force policy count<sup>1</sup> ('000)



Adjusted gross income<sup>2</sup> (USD m)



Earnings before interest and tax (EBIT)

**USD-362m**

in 2022

USD-278m

in 2021

- Increase in adjusted gross income (excluding COVID-19 impacts) of 21% driven by continued growth of the business
- Growth in adjusted gross income is higher than increase in operating expenses
- EBIT adversely affected by continued investment to grow the businesses globally and several non-recurring impacts. EBIT estimate for 2023 of around USD -250m


<sup>1</sup> Core business only, excluding transaction business

<sup>2</sup> Calculated as US GAAP EBIT adjusted for operating expenses, other overheads and investment gains/losses; gross of reinsurance

<sup>3</sup> 2021 restated to reflect lead costs from Americas distribution business


# iptiQ division strategy in action

Portfolio split by region and line of business  
(% of gross premiums written)



## Underwriting results


**Gross loss ratio** (as % of gross premiums earned)



- Gross loss ratio largely unchanged as claims experience, COVID-19 impacts, and business mix remain at similar levels to 2021

## Operational performance


**Operating expense ratio** (as % of gross premiums earned)



- Scalability of iptiQ's operating model contributes to improved productivity
- Growth of gross premiums earned and adjusted gross income continued to outpace operating expenses

## Business expansion

**Number of distribution partners**



- Net increase in distribution partners by 5, further supporting future business growth
- Growth in partnerships driven by the launch of the China business, while EMEA and Americas remained largely unchanged

# Group investments

# Investment result reflects steady increase in recurring income, though impacted by the decline in global equity markets

Return on investments (ROI)

Investment portfolio positioning (USD bn)



Net investment income (USD m)  
Recurring income yield (RIY)<sup>2</sup> (%)

## 2.0%

in FY 2022

## 3.2%

in FY 2021



- ROI of 2.0% for FY 2022, comprised of net investment income (+2.2%) and net realised losses (-0.2%)
- Net realised losses from credit impairments of USD 60m for FY 2022

- Decrease in market value of government bonds and credit investments mainly driven by rising interest rates and credit spread widening, partially offset by net purchases
- Equities and alternatives decrease due to mark-to-market losses (USD -0.6bn<sup>3</sup>) and net sales

- FY 2022 recurring income yield of 2.6% (3.0% in Q4) continues to trend positively on the back of a rising fixed income reinvestment yield (5.1% in Q4). Increase of recurring income in Q4 2022 of USD ~170m vs Q4 2021
- Overall net investment income of USD 2 274m is below prior year mainly due to a significantly lower contribution from private equity

<sup>1</sup> Includes credit bonds, mortgages and other loans


<sup>2</sup> From 2021 recurring income yield replaced running yield (income from short-term investments, listed equity dividends and real estate investment income added to fixed income and loans already included in running yield metric)

<sup>3</sup> Mark-to-market impact as part of net realised investment losses, including equity securities (net of hedges), private equity and Principal Investments

# Alternative Capital Partners


# Increased earnings contribution from Alternative Capital Partners

Fee and commission revenues (USD m)



- Revenues earned through alternative or traditional activities:
  - Commissions earned as a percentage of premium ceded
  - Fees earned as a percent of assets under management
  - Profit commissions
  - Structuring and placement fees on client transactions

Sidecar and fund platform<sup>1</sup> (USD bn)



- Despite a challenging capital raising environment, risk sharing sidecar and fund platform increased assets year-on-year

# Appendix

# Business segment results FY 2022

## Income statement

USD m	Reinsurance	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	Total FY 2022	Total FY 2021
<b>Revenues</b>								
Gross premiums written	39 834	23 848	15 986	8 198	868	-1 011	47 889	46 658
Net premiums written	37 302	22 826	14 476	6 124	491	-	43 917	43 220
Change in unearned premiums	-540	-798	258	-642	133	-	-1 049	-753
Premiums earned	36 762	22 028	14 734	5 482	624	-	42 868	42 467
Fee income from policyholders	250	-	250	-	-	-	250	259
Net investment income/loss – non participating	2 786	1 355	1 431	223	131	-271	2 869	3 373
Net realised investment gains/losses – non participating	70	-117	187	29	-102	-	-3	537
Net investment result – unit-linked	-43	-	-43	-	-	-	-43	63
Other revenues	28	27	1	3	429	-403	57	40
<b>Total revenues</b>	<b>39 853</b>	<b>23 293</b>	<b>16 560</b>	<b>5 737</b>	<b>1 082</b>	<b>-674</b>	<b>45 998</b>	<b>46 739</b>
<b>Expenses</b>								
Claims and claim adjustment expenses	-16 344	-16 344	-	-2 889	-38	-	-19 271	-17 181
Life and health benefits	-12 948	-	-12 948	-675	-434	-	-14 057	-14 992
Return credited to policyholders	-280	-	-280	-	-	-	-280	-431
Acquisition costs	-6 878	-5 106	-1 772	-748	-174	-	-7 800	-8 228
Operating expenses	-1 946	-1 106	-840	-793	-1 033	403	-3 369	-3 505
<b>Total expenses</b>	<b>-38 396</b>	<b>-22 556</b>	<b>-15 840</b>	<b>-5 105</b>	<b>-1 679</b>	<b>403</b>	<b>-44 777</b>	<b>-44 337</b>
<b>Income/loss before interest and tax</b>	<b>1 457</b>	<b>737</b>	<b>720</b>	<b>632</b>	<b>-597</b>	<b>-271</b>	<b>1 221</b>	<b>2 402</b>
Interest expenses	-605	-372	-233	-24	-212	271	-570	-571
<b>Income/loss before income tax expense/benefit</b>	<b>852</b>	<b>365</b>	<b>487</b>	<b>608</b>	<b>-809</b>	<b>-</b>	<b>651</b>	<b>1 831</b>
Income tax expense/benefit	-124	-53	-71	-114	67	-	-171	-394
<b>Net income/loss before attribution of non-controlling interests</b>	<b>728</b>	<b>312</b>	<b>416</b>	<b>494</b>	<b>-742</b>	<b>-</b>	<b>480</b>	<b>1 437</b>
Income/loss attributable to non-controlling interests	-	-	-	-8	-	-	-8	-
<b>Net income/loss attributable to shareholders</b>	<b>728</b>	<b>312</b>	<b>416</b>	<b>486</b>	<b>-742</b>	<b>-</b>	<b>472</b>	<b>1 437</b>

# Business segment results Q4 2022

## Income statement

USD m	Reinsurance	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	Total Q4 2022	Total Q4 2021
<b>Revenues</b>								
Gross premiums written	8 049	4 046	4 003	2 250	205	-191	10 313	10 748
Net premiums written	7 505	3 931	3 574	1 693	129	-	9 327	9 807
Change in unearned premiums	1 647	1 491	156	-336	62	-	1 373	906
Premiums earned	9 152	5 422	3 730	1 357	191	-	10 700	10 713
Fee income from policyholders	52	-	52	-	-	-	52	63
Net investment income/loss – non participating	718	326	392	65	68	-80	771	754
Net realised investment gains/losses – non participating	51	-1	52	-9	100	-	142	249
Net investment result – unit-linked	42	-	42	-	-	-	42	31
Other revenues	5	5	-	-	111	-103	13	8
<b>Total revenues</b>	<b>10 020</b>	<b>5 752</b>	<b>4 268</b>	<b>1 413</b>	<b>470</b>	<b>-183</b>	<b>11 720</b>	<b>11 818</b>
<b>Expenses</b>								
Claims and claim adjustment expenses	-3 402	-3 402	-	-775	-11	-	-4 188	-4 182
Life and health benefits	-3 164	-	-3 164	-85	-135	-	-3 384	-4 189
Return credited to policyholders	-120	-	-120	-	-	-	-120	-110
Acquisition costs	-1 753	-1 266	-487	-199	-47	-	-1 999	-2 010
Operating expenses	-480	-264	-216	-204	-312	103	-893	-1 023
<b>Total expenses</b>	<b>-8 919</b>	<b>-4 932</b>	<b>-3 987</b>	<b>-1 263</b>	<b>-505</b>	<b>103</b>	<b>-10 584</b>	<b>-11 514</b>
<b>Income/loss before interest and tax</b>	<b>1 101</b>	<b>820</b>	<b>281</b>	<b>150</b>	<b>-35</b>	<b>-80</b>	<b>1 136</b>	<b>304</b>
Interest expenses	-140	-96	-44	-5	-51	80	-116	-134
<b>Income/loss before income tax expense/benefit</b>	<b>961</b>	<b>724</b>	<b>237</b>	<b>145</b>	<b>-86</b>	<b>-</b>	<b>1 020</b>	<b>170</b>
Income tax expense/benefit	-172	-130	-42	-11	-77	-	-260	10
<b>Net income/loss before attribution of non-controlling interests</b>	<b>789</b>	<b>594</b>	<b>195</b>	<b>134</b>	<b>-163</b>	<b>-</b>	<b>760</b>	<b>180</b>
Income/loss attributable to non-controlling interests	1	1	-	-4	-	-	-3	-1
<b>Net income/loss attributable to shareholders</b>	<b>790</b>	<b>595</b>	<b>195</b>	<b>130</b>	<b>-163</b>	<b>-</b>	<b>757</b>	<b>179</b>

# Business segment results FY 2022

## Balance sheet

31 December 2022, USD m	Reinsurance	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	End FY 2022	End FY 2021
<b>Assets</b>								
Fixed income securities	66 138	38 918	27 220	7 922	513	-	74 573	86 985
Equity securities	1 378	1 110	268	116	620	-	2 114	3 978
Other investments	21 814	18 265	3 549	371	4 107	-10 224	16 068	16 693
Short-term investments	7 162	4 367	2 795	1 451	294	-	8 907	8 462
Investments for unit-linked business	330	-	330	-	-	-	330	468
Cash and cash equivalents	3 320	1 605	1 715	718	39	-	4 077	5 051
Deferred acquisition costs	7 195	2 675	4 520	489	437	-	8 121	8 142
Acquired present value of future profits	794	-	794	-	-	-	794	836
Reinsurance recoverable	4 076	1 865	2 211	6 413	273	-4 255	6 507	6 482
Other reinsurance assets	29 359	17 024	12 335	3 135	216	-636	32 074	29 407
Goodwill	3 650	1 859	1 791	184	29	-	3 863	3 970
Other	21 627	12 406	9 221	3 115	4 058	-15 552	13 248	11 093
<b>Total assets</b>	<b>166 843</b>	<b>100 094</b>	<b>66 749</b>	<b>23 914</b>	<b>10 586</b>	<b>-30 667</b>	<b>170 676</b>	<b>181 567</b>
<b>Liabilities</b>								
Unpaid claims and claim adjustments expenses	75 101	58 317	16 784	13 914	662	-4 259	85 418	84 096
Liabilities for life and health policy benefits	19 426	-	19 426	625	874	-	20 925	22 196
Policyholder account balances	4 850	-	4 850	-	-	-	4 850	5 147
Other reinsurance liabilities	18 842	16 842	2 000	5 341	361	-1 039	23 505	21 761
Short-term debt	720	720	-	-	909	-843	786	862
Long-term debt	14 632	4 962	9 670	499	2 971	-7 850	10 252	10 323
Other	24 813	13 389	11 424	1 335	2 659	-16 676	12 131	13 504
<b>Total liabilities</b>	<b>158 384</b>	<b>94 230</b>	<b>64 154</b>	<b>21 714</b>	<b>8 436</b>	<b>-30 667</b>	<b>157 867</b>	<b>157 889</b>
<b>Equity</b>								
Shareholders' equity	8 451	5 856	2 595	2 098	2 150	-	12 699	23 568
Non-controlling interests	8	8	-	102	-	-	110	110
<b>Total equity</b>	<b>8 459</b>	<b>5 864</b>	<b>2 595</b>	<b>2 200</b>	<b>2 150</b>	<b>-</b>	<b>12 809</b>	<b>23 678</b>
<b>Total liabilities and equity</b>	<b>166 843</b>	<b>100 094</b>	<b>66 749</b>	<b>23 914</b>	<b>10 586</b>	<b>-30 667</b>	<b>170 676</b>	<b>181 567</b>

# Total equity and ROE FY 2022

USD m	Total FY 2022
<b>Shareholders' equity at 31 December 2021</b>	<b>23 568</b>
Net income attributable to shareholders	472
Dividends	-1 825
Net change in unrealised gains/losses	-9 738
Other (including fx)	222
<b>Shareholders' equity at 31 December 2022</b>	<b>12 699</b>
Non-controlling interests	110
<b>Total equity at 31 December 2022</b>	<b>12 809</b>

## ROE calculation

USD m	Total FY 2022
<b>Net income/loss attributable to shareholders</b>	<b>472</b>
Opening shareholders' equity	23 568
Average shareholders' equity	18 134
<b>ROE FY 2022<sup>1</sup></b>	<b>2.6%</b>


## Shares outstanding<sup>2</sup>

in millions	
<b>As at 31 December 2022</b>	<b>289.0</b>
<b>Weighted average</b>	<b>289.0</b>



# Change in shareholders' equity mainly driven by net unrealised investment losses and dividend payment

USD m




# P&C underwriting performance

## P&C Reinsurance and Corporate Solutions


P&C Reinsurance	Combined ratio				Main drivers of change in FY 2022	Net premiums earned (USD m)	
	Q4 2021	Q4 2022	FY 2021	FY 2022		Q4 2022	FY 2022
Property	86.8%	62.4%	92.2%	98.7%	• Deterioration impacted by elevated large nat cat losses and inflation updates	2 222	9 091
Casualty	107.2%	120.4%	104.3%	109.6%	• Impacted by inflation updates, continued increases of liability reserves and a deterioration in motor	2 281	9 335
Specialty	85.9%	87.1%	89.4%	93.2%	• Favourable experience and positive prior-year development dampened by reserves related to the Ukraine war, an update of a large prior-year loss and inflation updates	919	3 602
<b>Total</b>	<b>96.0%</b>	<b>91.0%</b>	<b>97.1%</b>	<b>102.4%</b>		<b>5 422</b>	<b>22 028</b>
<b>Corporate Solutions</b>							
Property	67.4%	70.2%	80.9%	72.9%	• Improvement reflects profitable new business growth and lower-than-expected claims activity, absorbing less favourable prior-year development	521	1 798
Casualty	106.0%	113.9%	103.6%	108.5%	• Driven by prior-year man-made losses (mainly from UW years 2019 and prior) as well as assumption updates including for economic inflation	439	1 710
Specialty	77.4%	101.0%	76.3%	96.2%	• Deterioration reflects reserves related to the Ukraine war and a large man-made loss within aviation and space in Q4 2022	297	1 184
elipsLife <sup>1</sup>	103.2%	97.0%	99.6%	101.3%	• Result driven by adverse prior-year development and assumption updates	100	790
<b>Total</b>	<b>89.0%</b>	<b>93.1%</b>	<b>90.6%</b>	<b>93.1%</b>		<b>1 357</b>	<b>5 482</b>

# P&C Reinsurance: combined ratio split

## Quarterly performance (%)



## Full-year performance (%)



## Main drivers of change in FY 2022

- Current accident year (CAY) loss ratio excluding large losses increased vs. prior-year period, primarily due to higher-than-expected economic inflation. Loss ratio includes current accident year inflation reserves of USD 0.2bn<sup>1</sup> (USD 0.1bn in Q4 2022)
- Acquisition costs declined vs. prior-year period due to business mix change as well as improved commission ratio
- Operating expense ratio improved as a result of diligent cost management and favourable fx rate developments
- Prior-year development of USD -404m, driven by economic inflation as well as liability and motor reserve strengthening, partially offset by positive reserve development of broader portfolio
- Large man-made losses of USD 247m, including reserves related to the Ukraine war of USD 187m
- Large nat cat losses of USD 2.7bn<sup>2</sup> vs. USD 1.9bn expected

■ CAY losses excl. large losses    ■ Prior-year development    ■ COVID-19  
■ Acquisition costs    ■ Large man-made losses    ■ Ukraine war  
■ Operating expenses    ■ Large nat cat losses


Note: Large losses are defined as losses USD >20m in P&C Reinsurance

<sup>1</sup> Does not include implicit impacts of economic inflation on actual reported claims


<sup>2</sup> Net of reinstatement premiums of USD 0.2bn

# Corporate Solutions: combined ratio split

## Quarterly performance (%)



## Full-year performance (%)



- CAY losses excl. large losses
- Acquisition costs
- Operating expenses
- Prior-year development
- COVID-19
- Large man-made losses
- Large nat cat losses
- Ukraine war

## Main drivers of change in FY 2022

- Current accident year (CAY) loss ratio excluding large losses benefitted from improved portfolio resilience and continuous earn-through of rate increases, which more than offset assumption updates (including for economic inflation)
- Acquisition costs increased due to change in business mix and increased cessions
- Operating expense ratio improved as a result of diligent cost management and favourable fx rate developments
- Favourable prior-year development of USD 168m (vs. USD 330m in FY 2021, which benefitted from low accident year 2020 claims activity)
- Large nat cat losses of USD 229m (vs. USD 345m in FY 2021)
- Large man-made losses of USD 389m (vs. USD 249m in FY 2021), including reserves related to the Ukraine war of USD 147m

# L&H Reinsurance EBIT movements

## EBIT movements (USD m)

	FY 2021 <sup>3</sup>			FY 2022		
	Life	Health	L&H	Life	Health	L&H
<b>EBIT reported</b>	<b>-1 052</b>	<b>412</b>	<b>-299<sup>4</sup></b>	<b>285</b>	<b>304</b>	<b>720<sup>4</sup></b>
<b>Net operating margin, %</b>	<b>-9.0</b>	<b>8.6</b>	<b>-1.8</b>	<b>2.4</b>	<b>6.4</b>	<b>4.3</b>
Mortality/morbidity experience vs. expected <sup>1</sup>	102	9	111	-58	-40	-98
Valuation/assumption changes <sup>2</sup>	4	-36	-32	-29	-60	-89
VA/GMDB/B36	-18	-	-18	3	-	3
COVID-19 related claims	-1 945	-11	-1 956	-626	38	-588

- Mortality experience (excluding COVID-19) was negative across Asia and EMEA regions, while adverse morbidity experience was primarily driven by Asia
- Valuation and assumption changes were negative reflecting the outcome of various portfolio reviews across Asia
- COVID-19 losses decreased significantly compared to last year

<sup>1</sup> 'Expected' reflects latest best estimate of claims expected to be paid out

<sup>2</sup> Including valuation/assumption changes related to VA/GMDB/B36

<sup>3</sup> FY 2021 figures restated for Group items re-segmentation

<sup>4</sup> The total includes unallocated net realised gains of USD 341m in 2021 and USD 131m in 2022

# Return on investments (ROI) FY 2022


USD m	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	Total FY 2022	Total FY 2021
<b>Investment related net investment income</b>	<b>1 105</b>	<b>1 035</b>	<b>228</b>	<b>177</b>	<b>-271</b>	<b>2 274</b>	<b>2 834</b>
<i>Fixed income</i>	745	946	166	14	-	1 871	1 725
<i>Equities and alternative investments – incl. RE PE HF</i>	366	17	40	-10	-	413	1 332
<i>Other</i>	236	178	43	196	-297	356	154
<i>Investment expenses</i>	-242	-106	-21	-23	26	-366	-377
<b>Investment related net realised gains/losses</b>	<b>-205</b>	<b>105</b>	<b>-61</b>	<b>-69</b>	<b>-</b>	<b>-230</b>	<b>551</b>
<i>Fixed income</i>	-317	32	-12	-	-	-297	174
<i>Equities and alternative investments – incl. RE PE HF</i>	-271	17	-42	-64	-	-360	324
<i>Other</i>	383	56	-7	-5	-	427	53
<b>Other revenues</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Investment related operating income</b>	<b>900</b>	<b>1 140</b>	<b>167</b>	<b>108</b>	<b>-271</b>	<b>2 044</b>	<b>3 385</b>
Less income not related to investment return <sup>1</sup>	-72	-21	-21	-71	95	-90	-24
<b>Basis for ROI</b>	<b>828</b>	<b>1 119</b>	<b>146</b>	<b>37</b>	<b>-176</b>	<b>1 954</b>	<b>3 361</b>
<b>Average invested assets</b>	<b>57 216</b>	<b>35 067</b>	<b>10 415</b>	<b>4 244</b>	<b>-8 775</b>	<b>98 167</b>	<b>106 591</b>
<b>ROI</b>	<b>1.4%</b>	<b>3.2%</b>	<b>1.4%</b>	<b>0.9%</b>	<b>n.m.</b>	<b>2.0%</b>	<b>3.2%</b>
Insurance related net investment income	250	396	-5	-46	-	595	539
Insurance related net realised gains/losses	-10	56	84	2	-	132	20
Foreign exchange gains/losses	98	26	6	-35	-	95	-34
<b>Net investment income/loss – non participating</b>	<b>1 355</b>	<b>1 431</b>	<b>223</b>	<b>131</b>	<b>-271</b>	<b>2 869</b>	<b>3 373</b>
<b>Net realised investment gains/losses – non participating</b>	<b>-117</b>	<b>187</b>	<b>29</b>	<b>-102</b>	<b>-</b>	<b>-3</b>	<b>537</b>

- Decline in investment related net investment income due to a lower contribution from private equity and listed equity dividends
- Investment related net realised losses driven by mark-to-market losses on equities as well as fixed income trading positions, partially offset by derivative gains in 'Other'
- Insurance related net realised gains mainly driven by weather derivatives within Corporate Solutions

# Return on investments (ROI) Q4 2022

USD m	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	Total Q4 2022	Total Q4 2021
<b>Investment related net investment income</b>	<b>277</b>	<b>290</b>	<b>67</b>	<b>64</b>	<b>-79</b>	<b>619</b>	<b>683</b>
<i>Fixed income</i>	221	243	48	4	-	516	418
<i>Equities and alternative investments – incl. RE PE HF</i>	34	3	-	11	-	48	320
<i>Other</i>	86	69	23	54	-86	146	45
<i>Investment expenses</i>	-64	-25	-4	-5	7	-91	-100
<b>Investment related net realised gains/losses</b>	<b>13</b>	<b>51</b>	<b>-12</b>	<b>136</b>	<b>-</b>	<b>188</b>	<b>279</b>
<i>Fixed income</i>	22	-	-2	1	-	21	71
<i>Equities and alternative investments – incl. RE PE HF</i>	149	20	6	136	-	311	212
<i>Other</i>	-158	31	-16	-1	-	-144	-4
<b>Other revenues</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Investment related operating income</b>	<b>290</b>	<b>341</b>	<b>55</b>	<b>200</b>	<b>-79</b>	<b>807</b>	<b>962</b>
Less income not related to investment return <sup>1</sup>	-29	-13	-11	-10	22	-41	-7
<b>Basis for ROI</b>	<b>261</b>	<b>328</b>	<b>44</b>	<b>190</b>	<b>-57</b>	<b>766</b>	<b>955</b>
<b>Average invested assets</b>	<b>55 399</b>	<b>33 195</b>	<b>9 775</b>	<b>4 608</b>	<b>-9 040</b>	<b>93 937</b>	<b>108 426</b>
<b>ROI</b>	<b>1.9%</b>	<b>4.0%</b>	<b>1.8%</b>	<b>16.5%</b>	<b>n.m.</b>	<b>3.3%</b>	<b>3.5%</b>
Insurance related net investment income	49	102	-2	4	-1	152	71
Insurance related net realised gains/losses	18	5	2	-1	-	24	-20
Foreign exchange gains/losses	-32	-4	1	-35	-	-70	-10
<b>Net investment income/loss – non participating</b>	<b>326</b>	<b>392</b>	<b>65</b>	<b>68</b>	<b>-80</b>	<b>771</b>	<b>754</b>
<b>Net realised investment gains/losses – non participating</b>	<b>-1</b>	<b>52</b>	<b>-9</b>	<b>100</b>	<b>-</b>	<b>142</b>	<b>249</b>



# Overall investment portfolio



USD bn	P&C Re	L&H Re	Corporate Solutions	Group items	Consolidation	End FY 2022	End FY 2021
Cash and cash equivalents	1.6	1.7	0.7	0.1	-	4.1	5.0
Short-term investments	4.4	2.8	1.4	0.3	-	8.9	8.5
Government bonds	22.7	10.8	3.9	0.3	-	37.7	47.2
Credit bonds	16.2	16.4	4.0	0.2	-	36.8	39.8
Equities <sup>1</sup>	5.0	0.2	0.3	1.0	-	6.5	8.9
Mortgages and other loans	6.8	2.9	0.2	3.1	-8.7	4.3	3.9
Other investments (incl. policy loans)	7.6	0.7	0.1	0.5	-1.5	7.4	7.9
<b>Total</b>	<b>64.3</b>	<b>35.5</b>	<b>10.6</b>	<b>5.5</b>	<b>-10.2</b>	<b>105.7</b>	<b>121.2</b>

# Fixed income securities

USD m	Government bonds	Credit bonds
End FY 2021	47 205	39 780
End FY 2022	37 722	36 851






- Decrease in government bonds driven by market value losses, reflecting the impact of rising interest rates
- Decrease in credit bonds reflects the impact of rising interest rates as well as credit spread widening, partially offset by net purchases
- Credit bonds include corporate bonds (USD 32.8bn) and securitised products (USD 4.0bn)

# Equities and alternative investments

USD m	End FY 2021	End FY 2022
Equity securities	2 739	1 535
Private equity	3 054	3 301
Hedge funds	157	9
Real estate	5 569	5 752
Principal Investments	2 944	1 660
<i>Equity securities</i>	1 239	579
<i>Private equity</i>	1 705	1 081
<b>Total market value</b>	<b>14 463</b>	<b>12 257</b>

- Decrease in equities is due to net sales as well as mark-to-market losses
- Private equity reflects a reallocation from Principal Investments as well as net purchases, partially offset by valuation losses
- Hedge funds decrease driven by net sales
- Decrease in Principal Investments driven by sale of remaining position in Phoenix and valuation losses (mainly on FWD and CPIC) as well as a reallocation to private equity



# Overview of proposed capital management actions

- The Board of Directors will propose to the AGM 2023:
  - Regular dividend of USD 6.40 per share
  - Replacement of the existing authorised capital approval (up to 85 million shares), which expires at the AGM 2023, with a capital band that:
    - has an upper limit of 85 million shares, in line with the existing authorised capital approval
    - has a lower limit of 31.7 million shares (10% of outstanding shares)
    - expires at AGM 2025
  - The number of shares that can be issued prior to the 2025 AGM under the capital band and out of conditional capital where existing shareholders' subscription rights and advance subscription rights are excluded, is limited to 31.7 million (10% of outstanding shares), in line with the existing limit
- The Board of Directors will not propose to the AGM a public share buyback programme for 2023

# Sensitivities

(USD bn, pre-tax)

## Change in market values

(Equities and alternative investments, excl. real estate)

	-25%	-10%	+25%
Estimated impact on <b>shareholders' equity</b>	-0.9	-0.5	+1.4
Estimated impact on <b>economic net worth (EVM)</b>	-0.9	-0.5	+1.4
Estimated impact on <b>income/loss before income tax expense</b>	-0.9	-0.4	+1.3

## Change in interest rates

	-50bps	-25bps	+50bps	+100bps
Estimated impact on <b>shareholders' equity</b>	+2.2	+1.1	-2.1	-4.0
Estimated impact on <b>economic net worth (EVM)</b>	0.0	0.0	0.0	0.0

## Change in credit spreads

	-50bps	+50bps	+100bps
Estimated impact on <b>shareholders' equity</b>	+1.2	-1.2	-2.3
Estimated impact on <b>economic net worth (EVM)</b>	+1.3	-1.2	-2.4



# Premiums by country


2022 Gross premiums written and fees assessed against policyholders by country<sup>1</sup> (USD m)

	Life & Health	Non-Life	Total FY 2022	Total FY 2021
United States	7 006	14 434	21 440	20 094
United Kingdom	1 927	2 317	4 244	4 246
Australia	929	1 020	1 949	2 096
China	783	888	1 671	1 754
Canada	853	768	1 621	1 571
Germany	181	1379	1 560	1 549
Ireland	1 107	163	1 270	1 277
Japan	537	692	1 229	1 358
Netherlands	874	252	1 126	1 174
France	200	808	1 008	1 075
Bermuda	201	561	762	823
South Korea	346	381	727	649
Israel	453	171	624	703
Switzerland	60	559	619	1 015
Italy	86	500	586	469
Spain	78	494	572	553
India	94	391	485	465
New Zealand	387	95	482	535
Singapore	350	127	477	305
Brazil	72	361	433	317
Hong Kong	337	50	387	486
South Africa	181	197	378	354
Other	1 270	3 220	4 490	4 051
<b>Total</b>	<b>18 312</b>	<b>29 828</b>	<b>48 140</b>	<b>46 919</b>




# Premiums by line of business and region

Premiums earned and fee income by line of business (USD bn)



Premiums earned and fee income by geography (USD bn)



# Corporate calendar and contacts

## Corporate calendar

---

### 2023

16 March	<b>Publication of Annual Report 2022</b>	Zurich
12 April	<b>159<sup>th</sup> Annual General Meeting</b>	Zurich
04 May	<b>Q1 2023 Results</b>	Media Conference call
04 August	<b>H1 2023 Results</b>	Media conference
09 – 13 September	<b>Rendez-Vous de Septembre 2023</b>	Media conference
03 November	<b>9M 2023 Results</b>	Media conference call
01 December	<b>Investors' Day 2023</b>	Zurich

## Media Relations contacts

---

### Hotline

+41 43 285 71 71

### E-mail

Media\_Relations@swissre.com



# Cautionary note on forward-looking statements

Certain statements and illustrations contained herein are forward-looking. These statements (including as to plans, objectives, targets, and trends) and illustrations provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical fact or current fact.

Forward-looking statements typically are identified by words or phrases such as “anticipate”, “target”, “aim”, “assume”, “believe”, “continue”, “estimate”, “expect”, “foresee”, “intend” and similar expressions, or by future or conditional verbs such as “will”, “may”, “should”, “would” and “could”. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Swiss Re's (the "Group") actual results of operations, financial condition, solvency ratios, capital or liquidity positions or prospects to be materially different from any future results of operations, financial condition, solvency ratios, capital or liquidity positions or prospects expressed or implied by such statements or cause the Group to not achieve its published targets. Such factors include, among others:

- macro-economic events or developments including increased volatility of, and/or disruption in, global capital, credit, foreign exchange and other markets and their impact on the respective prices, interest and exchange rates and other benchmarks of such markets, and historically high inflation rates;
- the frequency, severity and development of, and losses associated with, insured claim events, particularly natural catastrophes, man-made disasters, pandemics, including the coronavirus ("COVID-19"), social inflation litigation, acts of terrorism or acts of war, including the ongoing war in Ukraine, and any associated governmental and other measures such as sanctions, expropriations and seizures of assets as well as the economic consequences of the foregoing;
- the Group's ability to comply with standards related to environmental, social and governance ("ESG"), sustainability and corporate social responsibility ("CSR") matters and to fully achieve goals, targets, or ambitions related to such matters;
- the Group's ability to achieve its strategic objectives;
- legal actions or regulatory investigations or actions, including in respect of industry requirements or business conduct rules of general applicability, the intensity and frequency of which may also increase as a result of social inflation;
- central bank intervention in the financial markets, trade wars or other protectionist measures relating to international trade arrangements, adverse geopolitical events, domestic political upheavals or other developments that adversely impact global economic conditions;
- mortality, morbidity and longevity experience;
- the cyclical nature of the reinsurance sector;
- the Group's ability to maintain sufficient liquidity and access to capital markets, including sufficient liquidity to cover potential recapture of reinsurance agreements, early calls of debt or debt-like arrangements and collateral calls due to actual or perceived deterioration of the Group's financial strength or otherwise;
- the Group's inability to realise amounts on sales of securities on the Group's balance sheet equivalent to their values recorded for accounting purposes;
- the Group's inability to generate sufficient investment income from its investment portfolio, including as a result of fluctuations in the equity and fixed income markets, the composition of the investment portfolio or otherwise;
- changes in legislation and regulation or the interpretations thereof by regulators and courts, affecting the Group or its ceding companies, including as a result of comprehensive reform or shifts away from multilateral approaches to regulation of global operations;
- matters negatively affecting the reputation of the Group, its board of directors or its management;
- the lowering, loss or giving up of one of the financial strength or other ratings of one or more companies in the Group, and developments adversely affecting its ability to achieve improved ratings;
- uncertainties in estimating reserves, including differences between actual claims experience and underwriting and reserving assumptions;
- policy renewal and lapse rates;
- the outcome of tax audits, the ability to realise tax loss carryforwards and the ability to realise deferred tax assets (including by reason of the mix of earnings in a jurisdiction or deemed change of control), which could negatively impact future earnings, and the overall impact of changes in tax regimes on the Group's business model;
- changes in accounting estimates or assumptions that affect reported amounts of assets, liabilities, revenues or expenses, including contingent assets and liabilities as well as changes in accounting standards, practices or policies;
- strengthening or weakening of foreign currencies;
- reforms of, or other potential changes to, benchmark reference rates;
- failure of the Group's hedging arrangements to be effective;
- significant investments, acquisitions or dispositions, and any delays, unforeseen liabilities or other costs, lower-than-expected benefits, impairments, ratings action or other issues experienced in connection with any such transactions;
- extraordinary events affecting the Group's clients and other counterparties, such as bankruptcies, liquidations and other credit-related events;
- changing levels of competition;
- the effects of business disruption due to terrorist attacks, cyberattacks, natural catastrophes, public health emergencies, hostilities or other events;
- limitations on the ability of the Group's subsidiaries to pay dividends or make other distributions; and
- operational factors, including the efficacy of risk management and other internal procedures in anticipating and managing the foregoing risks.

These factors are not exhaustive. The Group operates in a continually changing environment and new risks emerge continually. Readers are cautioned not to place undue reliance on forward-looking statements. Swiss Re undertakes no obligation to publicly revise or update any forward-looking statements, whether as a result of new information, future events or otherwise.

This communication is not intended to be a recommendation to buy, sell or hold securities and does not constitute an offer for the sale of, or the solicitation of an offer to buy, securities in any jurisdiction, including the United States. Any such offer will only be made by means of a prospectus or offering memorandum, and in compliance with applicable securities laws.

# Legal notice

©2023 Swiss Re. All rights reserved. You may use this presentation for private or internal purposes but note that any copyright or other proprietary notices must not be removed. You are not permitted to create any modifications or derivative works of this presentation, or to use it for commercial or other public purposes, without the prior written permission of Swiss Re.

The information and opinions contained in the presentation are provided as at the date of the presentation and may change. Although the information used was taken from reliable sources, Swiss Re does not accept any responsibility for its accuracy or comprehensiveness or its updating. All liability for the accuracy and completeness of the information or for any damage or loss resulting from its use is expressly excluded.